Activity ID
14061Expires
December 31, 2027Format Type
EnduringCME Credit
1Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
The goal of this program is to provide sustained education that will improve healthcare professionals’ knowledge, competence, and performance in adopting the latest best practices to optimize care of patients with schizophrenia.
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
At the conclusion of this activity, learners should be better able to:
· Identify the characteristics of novel and emerging therapeutic agents for schizophrenia beyond antidopaminergic antipsychotics, including mechanisms of action and pharmacokinetics.
· Differentiate evidence for efficacy and safety profiles of novel agents used in the treatment of schizophrenia.
· Explain the potential of novel antipsychotics in transforming clinical practice by addressing unmet needs of current schizophrenia treatments.
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Academic Medicine, Inpatient, Outpatient, Rural, Urban, VA/Military
